2-hydroxy-cyclopentanecarboxyaldehyde | 1080005-96-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydroxy-cyclopentanecarboxyaldehyde
• 英文别名: 2-Hydroxycyclopentanecarbaldehyde；2-hydroxycyclopentane-1-carbaldehyde
• CAS: 1080005-96-4
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: GPSUJFRHMYUDNV-UHFFFAOYSA-N

物化性质

• 沸点：
  205.0±33.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  己二醛 在 吡啶-N-氧化物 、 C₆H₁₁BrN₂O*C₃₂H₁₂BF₂₄^(1-)*H⁽¹⁺⁾ 作用下， 生成 1-环戊烯甲醛 、 2-hydroxy-cyclopentanecarboxyaldehyde
  参考文献：
  名称：

  氢键受体在有机胺催化中的作用

  摘要：

  氢键受体在有机烯胺催化的催化循环中起着重要作用。它可以通过氢与am（N质子化的烯胺中间体）发生氢键相互作用来有效地影响反应速率。我们的发现得到动力学实验和量子化学计算的支持。

  DOI：

  10.1002/chem.201502407

文献信息

• Asymmetric synthesis of propargylic alcohols via aldol reaction of aldehydes with ynals promoted by prolinol ether–transition metal–Brønsted acid cooperative catalysis
  作者：Enrique Gómez-Bengoa、Jesús M. García、Sandra Jiménez、Irati Lapuerta、Antonia Mielgo、José M. Odriozola、Itziar Otazo、Jesús Razkin、Iñaki Urruzuno、Silvia Vera、Mikel Oiarbide、Claudio Palomo

  DOI：10.1039/c3sc51027a

  日期：——

  A catalytic and highly stereoselective entry to propargylic alcohols and products derived thereof is reported based on an unprecedented cross-aldol coupling between unmodified aldehydes and ynals. The method requires an amine–metal salt–Brønsted acid ternary catalyst system and implies synergistic activation of the donor aldehyde via enamine and of the acceptor carbonyl via unique and reversible metal–alkyne complexation. Specifically, by using a combined α,α-dialkylprolinol silyl ether–CuI–PhCO2H catalyst system, remarkably high levels of diastereo- and enantioselectivity (anti/syn up to >20 : 1, ee up to >99%) are achieved.

  报告基于未改性醛和炔之间前所未有的交叉醛偶联，报道了一种催化性和高度立体选择性的丙炔醇及其衍生产品。该方法需要胺-金属盐-勃氏酸三元催化剂体系，并意味着通过烯胺对供体醛进行协同活化，以及通过独特且可逆的金属-炔烃络合对受体羰基进行协同活化。具体来说，通过联合使用δ,δ-二烷基脯氨醇硅基醚âCuIâPhCO2H催化剂体系，可实现极高的非对映选择性和对映体选择性（反/同步可达>20â:â1，ee可达>99%）。
• Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
  申请人：Sankyo Company Limited

  公开号：EP0542411A2

  公开（公告）日：1993-05-19

  Compounds of formula (I): in which: R¹ is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulphonyl, haloalkanesulphonyl or sulphamoyl; R² is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R³ is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is -NH- or oxygen or sulphur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.

  式(I)化合物： 其中R¹ 是氢、烷基、卤素、卤代烷基、羟基、烷氧基、卤代烷氧基、烷硫基、卤代烷硫基、氨基、烷酰基、卤代烷酰基、羧基、烷氧羰基、氨基甲酰基、氰基、硝基、烷磺酰基、卤代烷磺酰基或磺酰基；R² 是任选取代的烷酰基、任选取代的烯酰基、任选取代的环烷基羰基、取代的苯甲酰基或 5,6-二氢-1,4,2-二恶嗪-3-基；R³ 是氢、羟基、任选取代的烷氧基、烷氧基、烷甲氧基、烯甲氧基、环烷基羰基氧基、芳基羰基氧基、烷氧基羰基氧基、烷氧基羰基氧基、酞酰氧基、(5-甲基-2-氧代-1,3-二氧戊烯-4-基)甲氧基、(5-苯基-2-氧代-1,3-二氧戊烯-4-基)甲氧基、任选取代的氨基或硝基；Y 是-NH-或氧或硫；n 是 1 至 5；所述式（I）化合物的同系物和盐具有抑制血小板聚集的能力，因此可用于血栓和栓塞的治疗和预防。
• Treatment of laminitis with platelet aggregation inhibitors
  申请人：Dussler, Sabine

  公开号：EP2497475A1

  公开（公告）日：2012-09-12

  The present invention relates to the novel use of platelet aggregation inhibitors for the treatment and/or prevention of Laminitis in veterinary medicine. In particular the invention refers to the novel use of specific antiplatelet drugs for the treatment and/or prevention of Laminitis.

  本发明涉及在兽医学中使用血小板聚集抑制剂治疗和/或预防蹄叶炎的新方法。特别是，本发明涉及特定抗血小板药物在治疗和/或预防蹄叶炎方面的新用途。
• Selective apoptotic induction in cancer cells including activation of procaspase-3
  申请人：The Board of Trustees of the University of Illinois

  公开号：EP2659884A2

  公开（公告）日：2013-11-06

  Compounds and related methods for synthesis, and the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3, and particular embodiments are capable of direct activation of procaspase-3 and procaspase-7 to the effector forms of caspase-3 and caspase-7. Procaspase-3 levels can vary among cancer cell types; several types have relatively high levels and can have increased susceptibility to chemotherapy by compounds and methods herein. Therapeutic applications are relevant for a variety of cancer conditions and cell types, e.g. breast, lung, brain, colon, renal, adrenal, melanoma, and others.

  公开了化合物和相关的合成方法，以及化合物在治疗癌症和选择性诱导细胞凋亡疗法中的用途。所公开的化合物涉及对原蛋白酶（如原蛋白酶-3）的修饰，特定的实施方案能够将原蛋白酶-3和原蛋白酶-7直接激活为caspase-3和caspase-7的效应形式。Procaspase-3 的水平可因癌细胞类型而异；有几种癌细胞类型的 Procaspase-3 水平相对较高，可增加对本文所述化合物和方法化疗的敏感性。治疗应用适用于多种癌症病症和细胞类型，如乳腺癌、肺癌、脑癌、结肠癌、肾癌、肾上腺癌、黑色素瘤等。
• Compounds and methods for the treatment of cancer
  申请人：The Board of Trustees of the University of Illinois

  公开号：US10166229B2

  公开（公告）日：2019-01-01

  Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

  在有关诱导细胞死亡（如癌细胞）的实施方案中，公开了化合物和方法。公开了化合物及其合成和使用的相关方法，包括在治疗癌症和选择性诱导细胞凋亡的疗法中使用化合物。所公开的化合物涉及对原蛋白酶（如原蛋白酶-3）的修饰。在实施方案中，组合物能够激活procaspase-3。